Form 4: IRADIMED CEO Sells Shares Under 10b5-1 Plan

IRADIMED CEO Roger E. Susi sold 5,000 shares of common stock for approximately $356,000 through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, who serves as CEO, President, Chairman, and a 10% Owner of IRADIMED CORP (IRMD), reported sales of common stock.
• A total of 5,000 shares were sold on September 17, 2025, across two separate transactions.
• The first transaction involved the sale of 3,454 shares at a weighted average price of $71.0016 per share.
• The second transaction involved the sale of 1,546 shares at a weighted average price of $71.8808 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Susi on June 16, 2025.
• Following these transactions, Mr. Susi's indirect beneficial ownership through the Phillip Susi 2008 Dynasty Trust is 2,357,500 shares.
• Additional indirect beneficial ownership includes 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust.
• Mr. Susi disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Sentiment

Score: 5

Explanation: The filing reports a routine insider sale under a pre-arranged 10b5-1 plan, which is generally considered neutral as it reflects planned liquidity or diversification rather than a reaction to new company-specific news.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and systematic approach to stock disposition rather than an immediate reaction to new information.

Negatives

• Insider sales, even under a 10b5-1 plan, represent a reduction in direct or indirect ownership by a key executive and significant shareholder.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general implication of an insider selling shares.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitors.

Related Party Transactions

• The reported sales were made from shares indirectly beneficially owned through the Phillip Susi 2008 Dynasty Trust.
• Roger E. Susi also indirectly beneficially owns shares through the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, potentially viewed neutrally given the 10b5-1 plan, but could be interpreted as a slight negative by some.
• Management: The CEO is executing a pre-planned diversification or liquidity event.

Key Dates

Recommendation

The filing reports a routine insider sale under a pre-arranged 10b5-1 plan, which does not inherently signal a change in company fundamentals or management's long-term outlook. The transaction is relatively small compared to the reporting person's total beneficial ownership, suggesting no immediate reason to alter investment strategy based solely on this disclosure.

Keywords

IRADIMED, IRMD, insider trading, stock sale, Form 4, 10b5-1, CEO, director, 10% owner